Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from AdAlta Ltd. ( (AU:1AD) ) is now available.
AdAlta’s subsidiary AdCella has expanded its clinical advisory board for lead asset BZDS1901, adding two prominent Australian oncologists with deep expertise in mesothelioma, immunotherapy, and CAR-T cell therapies. The enlarged board now spans five hospital systems that already administer commercial CAR-T products, potentially seeding future trial sites and strengthening clinical input into BZDS1901’s development.
The advisory board will guide Phase 1 trial design, optimise positioning of BZDS1901 within mesothelioma treatment pathways, and identify additional tumour indications and international partners for later-stage development. This move underpins AdCella’s strategy to link Asian CAR-T innovation with Western regulatory and clinical infrastructure, potentially accelerating BZDS1901’s progression and enhancing AdAlta’s competitive footing in the fast-growing solid tumour cell therapy market.
The most recent analyst rating on (AU:1AD) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on AdAlta Ltd. stock, see the AU:1AD Stock Forecast page.
More about AdAlta Ltd.
AdAlta Limited is an ASX-listed clinical-stage biotechnology company focused on cellular immunotherapies for solid cancers, an area that remains underserved despite representing about 90% of all tumours. Through its AdCella subsidiary, it in-licenses differentiated T cell therapies from Asian developers, then establishes FDA-regulated manufacturing and runs early-phase trials in Australia to position these assets for partnering with larger biopharmaceutical companies.
AdCella’s lead asset, BZDS1901, is a first-in-class mesothelin-targeted, armoured CAR-T therapy for mesothelioma and other solid tumours including lung and gynaecological cancers, designed to secrete its own immune checkpoint inhibitor and manufactured rapidly without viral vectors. Separately, AdAlta is advancing AD-214, a first-in-class fusion protein for fibrotic lung and kidney diseases, now partnering-ready after Phase I success, and WD-34, an i-body-based malaria prophylaxis and treatment candidate at discovery stage.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$10.2M
For an in-depth examination of 1AD stock, go to TipRanks’ Overview page.